通道阻塞剂和牙扩大之间的关联:一个病例控制研究
Giuseppe Mainas1, Pasquale Santamaria1, Noha Zoheir1
1Periodontology Unit, Centre for Host Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, UK.
Journal of dentistry
|August 19, 2024
概括
通道阻塞剂 (CCB) 可能导致牙扩大. 这项研究发现,不良的牙间清洁和II型糖尿病是危险因素,GCF和唾液中的生长因子和炎症标志物增加.
科学领域:
- 牙周病学 牙周病学
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 通道阻塞剂 (CCB) 经常被用于高血压.
- 使用CCB与药物诱导的牙扩大 (DIGE) 有关.
- 导致DIGE的特定因素和生物标志物需要进一步调查.
研究的目的:
- 在使用CCB的患者中识别与DIGE相关的因素.
- 分析DIGE和没有DIGE的CCB患者的唾液和牙沟液 (GCF) 概况.
- 为了比较不同患者群体的生物标志物水平.
主要方法:
- 包括131名参与者,其中91名接受高血压CCB治疗.
- DIGE在临床上得到了评估,并且与患者因素有关.
- 唾液和GCF样本使用多重免疫试验对生物标志物进行了分析,与组匹配的对照进行了分析.
主要成果:
- 22%的CCB患者发生了DIGE.
- 缺乏牙间清洁和II型糖尿病与DIGE有关.
- 在DIGE患者中发现VEGF,EGF和MMP-8以及唾液MMP-8的GCF水平升高.
结论:
- 这项研究是首次在DIGE患者和对照组中检查唾液和GCF生物标志物.
- 研究结果表明,炎症过程,组织损伤和生长因子 (VEGF) 都与DIGE有关.
- 需要进一步的研究来验证这些生物标志物并阐明病原机制.
关键词:
阿姆洛迪平氨酸是如何使用的通道阻塞剂 通道阻塞剂牙裂液是牙裂液中的一种液体.牙牙过度生长的情况尼菲迪平因 (nifedipine) 是一种尼菲迪平因 (nifedipine) 的一种药物.牙周病是指牙周病的发生.这是唾液的唾液.更多相关视频
相关概念视频
Antihypertensive Drugs: Action of Calcium Channel Blockers
477
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
477
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
467
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
467
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
800
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
800
Antiepileptic Drugs: Calcium Channel Blockers
350
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
350
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
149
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
149


